Orthobiologics - ATSNJ
Transcript of Orthobiologics - ATSNJ
![Page 1: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/1.jpg)
OrthobiologicsBrad J. Bernardini MD FAAOS
![Page 2: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/2.jpg)
Objectives
• Discuss relevance to sports medicine
• Briefly review definitions & regulatory process.
• Discuss basic science and theoretic uses.
• Review current clinical applications.
• Brief literature review and evidence.
• Summary & Questions!
![Page 3: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/3.jpg)
What are Orthobiologics?
• “Biologic substances used to augment musculoskeletal healing rates and alter inflammatory pathways”
![Page 4: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/4.jpg)
Sports Medicine Applications
• Augment the acute healing process
• Eliminate chronic or recurrent inflammatory conditions
• Enhance soft tissue reconstructive surgery
• Joint preservation
• More rapid return to play?
![Page 5: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/5.jpg)
Common Use Orthobiologics
• PRP - Platelet Rich Plasma
• PPP - Platelet Poor Plasma
• Stem Cells - “Mesenchymal stem cells” (MSC)
• Growth Factors - IL-1, IL-6, PDGF, TGF-B, VEGf, TNF, *ILRAP
![Page 6: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/6.jpg)
FDA Process
• 1997RegulationsonHumanCells,Tissues,andCellular/Tissue-BasedProducts(HCT/P’s)intendedforHumanuse
• LowRisk(361)vsHighRisk(351)• Manipulation /Systemic/Homologous /Combinations
• 351PathwayifconsideredHighRisk:Complexpathwayrequiring:• Processdevelopment andvalidation/Pre-InvestigationalApplications /BiologicLicensingApplications
/ClinicalProtocolDevelopment/Phase1,2,and3ClinicalTrials
• PRPconsidered LowRisk- 361Pathway(Nopremarketclinicaltrials)• MSCarevariableanddependentonmeeting theinclusioncriteriafor351pathway
![Page 7: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/7.jpg)
PRP• Concentration of autologous
blood w 4-8x concentration of platelets and GF’s
• PRP categories:
• Leukocyte poor (LP-PRP)
• Leukocyte rich (LR-PRP)
• Commercial centrifuge systems used in office and operating room
• Preparation and system preferences can yield different subtypes
![Page 8: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/8.jpg)
PRP - Mechanism of action
• Attraction of MSC’s / Macrpophages / Fibroblasts / *Alters Inflammatory environment
• Stimulation of cell proliferation and extracellular matrix protein production
• Promotes healing
![Page 9: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/9.jpg)
PPP - Platelet Poor Plasma
• PPP - The result of a second centrifuge spin of LP-PRP which removes Platelets
• Aids in Myoblast differentiation vs. proliferation
• May be most useful in muscle injury vs PRP
![Page 10: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/10.jpg)
”Stem Cells”
• Should be referred to as Mesenchymal Stem Cells for our purposes
• NOT Pleuripotential!
• Common sources are Adipose, Bone Marrow, Amniotic tissue, and banked Placental tissue
• They are very safe, but still poorly understood!
![Page 11: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/11.jpg)
MSC Mechanism of action
![Page 12: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/12.jpg)
MSC Mechanism of action
• Differentiate into terminal cells
• Secrete growth factors
• Encourage cell migration and tissue repair
• Reduces inflammation
![Page 13: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/13.jpg)
PRP & MSC Ortho Applications
• Articular Cartilage Injury
• *Osteoarthritis symptom relief
• Meniscus & ACL surgery
• Rotator Cuff Repair
• Chronic Tendinopathies
• Muscle Injury
![Page 14: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/14.jpg)
Literature Review
![Page 15: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/15.jpg)
Articular Cartilage & Osteoarthritis
• *LP-PRP improves clinical outcomes in OA Knee 3-12 months in 75%
• Prevention of cartilage damage and disease modification through GF alteration
• MSC’s may further improve results, but more costly and assoc. w/ harvest morbidity
• Surgical cartilage restoration w PRP & MSC’s shown to increase healing rates and quality of tissue
• *Scaffold and matrix delivery systems are a rapid growing area of research
![Page 16: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/16.jpg)
ACL & Meniscus Preservation
• Early studies showing promise for scaffold augmentation of ACL
• Improved ACL Graft maturation up to 40% faster
• Small patient populations and poor study design
• *PRP trend toward increased healing rates in current studies
• Meniscal preservation surgery increasing in frequency
• PRP & MSC augmentation may improve healing rates and aid in prevention of OA
• Early studies with small patient populations and fair study design
![Page 17: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/17.jpg)
Rotator Cuff Repair
• Animal studies have shown MSC’s in addition to scaffold or matrix delivery systems to be successful
• Improved healing rates / decreased muscular atrophy / decreased fatty infiltration of muscle
• PRP has not shown the same potential in the shoulder with Animal studies
• PRP may be beneficial in non-op management of rotator cuff tears
• *Improves the inflammatory environment and decreases pain
![Page 18: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/18.jpg)
Chronic Tendinopathy
• *LR-PRP strongly favored for these applications
• Excellent clinical outcomes for PRP in Tennis Elbow and Patellar Tendinosis
• Plantar Fasciitis showing moderately successful outcomes
• Less favorable for other anatomic tendinopathies: Achilles, Rotator Cuff, Hamstring…
![Page 19: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/19.jpg)
Muscle Injury
• PRP & MSC have a limited role in muscle regeneration
• PPP appears to have the most promise
• *Favors myoblast differentiation which results in muscle regeneration
• Limits scar tissue formation
• Improved pain relief during healing
![Page 20: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/20.jpg)
Summary
![Page 21: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/21.jpg)
Questions?
![Page 22: Orthobiologics - ATSNJ](https://reader031.fdocuments.net/reader031/viewer/2022012417/61722d900a8d4114d709b81d/html5/thumbnails/22.jpg)
Thank You!